Valerie's Cancer Detection Journey

Valerie's Cancer Detection Journey

Although Valerie didn’t have symptoms, she took the Galleri® test, which found a positive cancer signal. After additional evaluations, it was confirmed she had early-stage gallbladder cancer and was able to take action.

Listen Now

Up Next

A New Cancer Detection Paradigm is Needed

A Grail lab technician working

A New Cancer Detection Paradigm is Needed

Despite significant advancements in cancer treatment and prevention, cancer is expected to claim nearly 610,000 American lives in 2023 according to this year’s report from the American Cancer Society (ACS).

Read More

Up Next

Mary's Early Cancer Detection

Mary reading at kitchen table

Mary's Early Cancer Detection

Mary’s physician gave her a clean bill of health at her annual physical. Then, a multi-cancer early detection test found a positive cancer signal in her blood.

Up Next

Sir Harpal Kumar’s Keynote Address at WIRED UK

Sir Harpal Kumar

Sir Harpal Kumar’s Keynote Address at WIRED UK

Recently at WIRED UK Health in London, Sir Harpal Kumar, President Biopharma Business and Europe at GRAIL, gave a keynote address on the cancer landscape in the UK, the creation and history of GRAIL.

Watch Now

Up Next

Shifting Cancer Detection and Treatment Earlier

A Grail lab technician working

Shifting Cancer Detection and Treatment Earlier

We like to think of an elusive “miracle cure” or “silver bullet” for cancer, but it’s more likely that truly transforming cancer today and in the foreseeable future won’t take the form of a new pill, infusion or other medical therapy.

Read More

Up Next

Valerie's Cancer Detection Journey

Our Mission

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.

Join Our Team
A Grail lab technician working
The Galleri® Test

The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Learn More
Multi-Cancer Early Detection

Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.

Learn More
Methylation

GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.

Learn More

Who We Are

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.

Learn About Us
Grail lab technicians working

On this monthly podcast, Host Kim Thiboldeaux explores topics relating to multi-cancer early detection, such as its origin and evolution, the science behind it, and insight into how this technology has the potential to shift the cancer paradigm.